

# 2018

WHO 2016

[1]

4

3

1. 450  $10^9/L$

2.

1

3. BCR-ABL+

WHO

4. JAK2 CALR MPL

2013

[2]

1.

2.

3.

4.

1.

2.

3.

4.

1.

2.

(2016 ) [3]

JAK2V617F CARL MPL

- 1.
- 2.
- 3.

(2016 ) [3]

---



---

|          |   |             |                    |    |         |                    |     |    |  |
|----------|---|-------------|--------------------|----|---------|--------------------|-----|----|--|
| CR       | 4 |             |                    |    |         |                    |     |    |  |
|          |   |             |                    | 12 |         |                    |     |    |  |
|          |   | MPN-SAF TSS |                    | 10 |         |                    |     |    |  |
|          |   |             | 12                 |    | PLT 400 | 10 <sup>9</sup> /L | WBC | 10 |  |
|          |   |             | 10 <sup>9</sup> /L |    |         |                    |     |    |  |
|          |   |             |                    |    |         |                    |     | 1  |  |
| PR       | 4 |             |                    |    |         |                    |     | 12 |  |
|          |   | MPN-SAF TSS |                    | 10 |         |                    |     |    |  |
|          |   |             | 12                 |    | PLT 400 | 10 <sup>9</sup> /L | WBC | 10 |  |
|          |   |             | 10 <sup>9</sup> /L |    |         |                    |     |    |  |
| NR<br>PD |   | PR          |                    |    |         |                    |     |    |  |

---

MPN-SAF TSS

2002 [4]

1. 95%
2. 70%

3. 30%
4. 30%
- [ ] 100%

[1]Arber D, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood 2016;127:2391-2405.

[2] . [M]. : 2013,154

[3] . (2016  
) [J]. 2016,37 10 833-835

[4] . [M]. 2002:173-180